In 2020, auditor KPMG said there was a “material uncertainty” over Irish biotech firm Nuritas. Now, having raised $45m from backers, there are no such concerns, even if its retained losses widened last year.
With a new US headquarters and a cross-Atlantic move on the horizon, Nuritas CEO and founder Dr Nora Khaldi discusses what led to the relocation and her plans for the next chapter of the company.
© 2023 Currency Media Limited
